Body weight is a robust predictor of clinical progression in Huntington disease. van der Burg JMM, Gardiner SL, Ludolph AC, Landwehrmeyer GB, Roos RAC, Aziz NA Ann Neurol 2017; 82:479-483 Abstract Background: Unintended weight loss is a hallmark of Huntington disease (HD), but it is unknown to what extent weight loss impacts the rate of… Read More Does body weight influence the speed of progression in Huntington’s disease?
A double blind, placebo-controlled study of rituximab in patients with stiff person syndrome. Dalakas MC, Rakocevic G, Dambrosia JM, Alexopoulos H, McElroy B. Ann Neurol 2017; 82:271-277. Abstract Objective In Stiff-Person Syndrome (SPS), an antibody-mediated impaired GABAergic neurotransmission is believed to cause muscle stiffness and spasms. Patients improve with GABA-enhancing drugs and IVIg, but several… Read More Is rituximab any good for stiff person syndrome?
The antimyotonic effect of lamotrigine in non-dystrophic myotonias: a double-blind randomized study Andersen G, Hedermann G, Witting N, Duno M, Andersen H, Vissing J Brain 2017; 140:2295-2305. Abstract Background: Mexiletine is the only drug with proven effect for treatment of non-dystrophic myotonia, but mexiletine is expensive, has limited availability and several side effects. There is… Read More Should lamotrigine be used first line in the treatment of myotonia?
Multiple biomarkers improve the prediction of multiple sclerosis in clinically isolated syndromes Martinelli V, Dalla Costa G, Messina MJ, et al. Acta Neurol Scand 2017; 136:454-461. Abstract Objectives: Since its introduction, MRI had a major impact on the early and more precise diagnosis of multiple sclerosis (MS), and the 2010 diagnostic criteria even allow a… Read More What factors predict the development of MS after the first attack of inflammation?
A population-based survey of risk for cancer in individuals diagnosed with myotonic dystrophy Abbott D, Johnson NE, Cannon-Albright LA Muscle Nerve 2016; 54:783-785. Abstract Introduction: The risk of cancer in patients diagnosed with myotonic dystrophy (DM) is reported for the homogeneous Utah population. Methods: Clinical data accessed from the largest Utah healthcare providers have been… Read More Should people with myotonic dystrophy be counselled on the risk of cancer?
The drug armoury for multiple sclerosis (MS) is ever-expanding. This topic has been extensively covered by our sister blog, The Neurology Lounge, in the blog posts titled Which are the remarkable drugs which have transformed the treatment of MS, Multiple sclerosis treatment: new kids on the block, The emerging progress from the world of MS, and How good is… Read More The innovative treatments relieving the burden of people with multiple sclerosis